Abstract:Abstract Background Individuals with Down Syndrome (DS) have an increased genetic risk for developing Alzheimer’s Disease (AD), due to a higher expression of genes related to the pathophysiological development of the disease and to the inflammatory process. Brain damage is already substantial when the first clinical signs of AD appear, it is essential to study therapeutic alternatives that delay its development. As lithium carbonate has been identified as a neuroprotective and neuroplastic agent in neurodegeneration, the aim of this study is to evaluate the treatment effect of lithium carbonate in the neuroinflammation and long‐term memory of Ts65Dn animal model of DS. Method Ts65Dn mice (trisomy confirmed by genotyping) were treated with a lithium carbonate microdose (0.25 mg/kg dissolved in water) for 18 months and compared to non‐treated animals. To evaluate the treatment, [ 11 C]PK11195 PET images were acquired at the ages of 5, 14, 20 and 24 months. Whole brain images were quantified in SUV (Standardized Uptake Value) and long‐term memory was assessed by the novel object recognition test (1). Result [ 11 C]PK11195 uptake was increased at 14 months in the non‐treated animals when compared to the respective age of 5 months (+29%), although not statistically significant. However, when mice were treated with lithium, this increase was not detected. Compared to 14 months, at the ages of 20 and 24 months, there was a decreased uptake in the non‐treated animals (Ts65Dn: ‐52%, p = 0.01 at 20 months; Ts65Dn: ‐59%, p = 0.006; at 24 months) and whereas in Ts65Dn‐lithium, the uptake did not change significantly among the ages. There was a decrease in the long‐term memory index in the non‐treated animals, at the ages of 20 (p = 0.03) and 24 months (p = 0.009), compared to 14 months‐old whereas in the treated animals the memory was preserved. Conclusion The treatment with lithium carbonate prevented glial cells alterations during life‐span and preserved long‐term memory of a Down syndrome animal model indicating that this treatment can contribute to a healthy brain aging in this syndrome.

Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome.

Glucagon-like Peptide-1 Cleavage Product GLP-1(9-36) Amide Rescues Synaptic Plasticity and Memory Deficits in Alzheimer's Disease Model Mice.

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice

The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice

Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome

γ‐Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer‐Related Pathologies in a Mouse Model of Down Syndrome

Maternal choline supplementation protects against age-associated cholinergic and GABAergic basal forebrain neuron degeneration in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease

CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation

Prenatal treatment with preimplantation factor improves early postnatal neurogenesis and cognitive impairments in a mouse model of Down syndrome

Adult choline supplementation in a Down syndrome model reduces co-morbidities and improves cognition

A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease

Assessing the Benefit of Dietary Choline Supplementation Throughout Adulthood in the Ts65Dn Mouse Model of Down Syndrome

Reversal of neurodevelopmental impairment and cognitive enhancement by pharmacological intervention with the polyphenol polydatin in a Down syndrome model

Formoterol, a Long-Acting β2 Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down Syndrome

Lithium carbonate treatment decrease neuroinflammation and ameliorates long‐term memory in a Down syndrome animal model

Glucose 6 phosphate dehydrogenase overexpression rescues the loss of cognition in the double transgenic APP/PS1 mouse model of Alzheimer's disease

Maternal choline supplementation rescues early endosome pathology in basal forebrain cholinergic neurons in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease

RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome

DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.

A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice

Forebrain Shh overexpression improves cognitive function in a Down syndrome mouse model and euploid littermates